Related Experiment Videos
Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy
J A Howe1, G W Demers, D E Johnson
1Canji Incorporated, 3525 John Hopkins Court, San Diego, California 92121, USA. john.howe@canji.com
Abstract:
The oncolytic effect of adenoviruses may provide an efficient means to destroy tumor tissue if viruses could be developed with sufficient selectivity and efficacy. In this report we have characterized several adenoviruses, each with different mutations in the E1 region, for selective cytopathic effect in tumor cells in vitro and for their ability to inhibit tumor growth in vivo. Of the E1 mutants tested, we have identified one, E1Adl01/07, which preferentially induces cytopathic effects in a range of tumor cells versus primary cells. In addition, E1Adl01/07 significantly inhibited tumor growth and increased survival of mice in several models of human cancer. These results suggest that E1Adl01/07 might serve as an effective cancer therapeutic, combining both selectivity and efficacy.
Insights
Researchers developed a novel adenovirus with mutations in the E1 region, E1Adl01/07, demonstrating selective tumor cell destruction and significant inhibition of human cancer growth in vivo. This engineered oncolytic virus shows promise as an effective cancer therapeutic.
Area of Science:
- Oncology
- Virology
- Gene Therapy
Background:
- Adenoviruses exhibit oncolytic potential for tumor destruction.
- Developing selective and effective oncolytic viruses remains a challenge.
Purpose of the Study:
- To characterize E1 region-mutated adenoviruses for selective tumor cell killing.
- To evaluate the in vivo efficacy of these mutants in inhibiting tumor growth.
Main Methods:
- In vitro characterization of cytopathic effects in tumor versus primary cells.
- In vivo studies using mouse models of human cancer to assess tumor growth inhibition and survival.
Main Results:
- Identified E1Adl01/07 as a mutant with preferential cytopathic effects on tumor cells.
- E1Adl01/07 significantly inhibited tumor growth and improved survival in multiple human cancer models.
- Demonstrated both selectivity and efficacy of the E1Adl01/07 adenovirus.
Conclusions:
- E1Adl01/07 shows potential as a selective and effective oncolytic cancer therapeutic.
- Engineered adenoviruses with specific mutations can enhance therapeutic outcomes.